Journal
CANCER LETTERS
Volume 459, Issue -, Pages 30-40Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.05.025
Keywords
PI3K/AKT pathway; MAPK/ERK pathway; Targeted cancer therapy; Protein kinase inhibitors; ONC201
Categories
Funding
- National Natural Science Foundation of China [81772842, 81802947]
Ask authors/readers for more resources
Phosphatidylinositol 3-kinase (PI3K)/AKT pathway regulates cell growth, proliferation, survival, mobility and invasion. Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is also an important mitogenic signaling pathway involved in various cellular progresses. AKT, also named protein kinase B (PKB), is a primary mediator of the PI3K signaling pathway; and ERK at the end of MAPK signaling is the unique substrate and downstream effector of mitogen-activated protein/extracellular signal-regulated kinase (MEK). The AKT and ERK signaling are both aberrantly activated in a wide range of human cancers and have long been targeted for cancer therapy, but the clinical benefits of these targeted therapies have been limited due to complex cross-talk. Novel strategies, such as AKT/ERK dual inhibitors, may be needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available